Tissue Regenix Group, the Leeds-based regenerative med-tech company, has expanded its manufacturing pipeline in the US.
The AIM listed company has signed a ten-year lease agreement on a 21,000 sq ft facility to expand processing capacity at its manufacturing base in San Antonio, Texas.
The agreement also includes the option to purchase the facility at a later date, the company said.
Situated on adjacent land to the Group’s current 13,700 sq. ft. facility, the new facility will be brought on stream in a phased plan to meet the growing commercial demand for the company’s novel product portfolio.
Phase one will commence immediately with part of the new building being converted into office, distribution and warehouse space, allowing for additional clean rooms to be built in the original facility, which are expected to be operational by the end of H1 2020.
Over time, it is planned for further processing and packaging clean rooms to be built in the new facility therefore, increasing the company’s ability to process more tissue and produce products.
“I am delighted that we have secured this additional facility to support our ambitious growth plans,” said Gareth Jones, interim CEO of Tissues Regenix Group.
“The Group has undertaken a number of operational initiatives in order to increase production capabilities and meet the growing market demand for our products.
“Having commenced a second shift at the beginning of the year in our current facility in San Antonio, the phased build out of this new facility will allow us to meet the growing requirements of our customers well into the future.”